Results 131 to 140 of about 84,026 (244)

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Arthritis &Rheumatology, EarlyView.
Objective Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Editorial: The role of expectations on treatment outcomes: from the experimental context to the clinical practice

Frontiers in Psychology
Eleonora Maria Camerone, Giacomo Rossettini, Giacomo Rossettini, Joel E. Bialosky, Joel E. Bialosky, Elisa Carlino   +5 more
doaj   +1 more source

Neural and molecular changes during a mind-body reconceptualization, meditation, and open label placebo healing intervention. [PDF]

Commun Biol
Jinich-Diamant A, Simpson S, Zuniga-Hertz JP, Chitteti R, Schilling JM, Bonds JA, Case L, Chernov AV, Dispenza J, Maree J, Amkie Stahl NE, Licamele M, Fazlalipour N, Devulapalli S, Christov-Moore L, Reggente N, Poirier MA, Moeller-Bertram T, Patel HH.   +18 more
europepmc   +1 more source

Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial. [PDF]

Oncologist, 2022
Yennurajalingam S, Azhar A, Lu Z, Rodriguez AJ, Arechiga AB, Guerra-Sanchez M, Stanton P, Andersen CR, Urbauer DL, Bruera E.   +9 more
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP‐LN Trial

Arthritis &Rheumatology, Accepted Article.
Objectives Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon (IFN) signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, NCT02547922). We studied
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Talking placebo: a qualitative study of patients' attitudes toward open-label placebo implementation into clinical practice. [PDF]

Front Psychol
Frey Nascimento A, Bakis B, Gaab J, Schneider T, Papadopoulou A, Ritter M, Bernstein MH, Blease CR, Locher C.   +8 more
europepmc   +1 more source

The impact of pharmaceutical form and simulated side effects in an open-label-placebo RCT for improving psychological distress in highly stressed students. [PDF]

Sci Rep, 2023
Winkler A, Hahn A, Hermann C.
europepmc   +1 more source

A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated with Colchicine Prophylaxis

Arthritis &Rheumatology, Accepted Article.
Objective This study investigated that serum metabolomics, prior to ULT initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n=409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun, Lingfang Xu, Haibing Chen, Mingshu Sun, Zhiqiang Li, Rui Li, Lidan Ma, Hui Zhang, Aichang Ji, Yuwei He, Na Wu, Le Yan, Robert Terkeltaub, Changgui Li   +13 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Changes in neural processing and evaluation of negative facial expressions after administration of an open-label placebo. [PDF]

Sci Rep, 2022
Schienle A, Unger I, Schwab D.
europepmc   +1 more source